相似文献
1
Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl.
Br J Pharmacol. 1996 Apr;117(8):1756-60. doi: 10.1111/j.1476-5381.1996.tb15350.x.
2
Chronic inhibition of the high-affinity dopamine uptake system increases oxidative damage to proteins in the aged rat substantia nigra.
Free Radic Biol Med. 1997;23(1):1-7. doi: 10.1016/s0891-5849(96)00405-4.
3
Deprenyl induces the tyrosine hydroxylase enzyme in the rat dopaminergic nigrostriatal system.
Brain Res Mol Brain Res. 1997 Jun;46(1-2):31-8. doi: 10.1016/s0169-328x(96)00270-7.
4
R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
J Neural Transm Suppl. 1987;25:45-66.
5
L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Neurochem Int. 2006 Jul;49(1):28-40. doi: 10.1016/j.neuint.2005.12.016. Epub 2006 Feb 21.
6
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
J Neural Transm (Vienna). 2001;108(8-9):985-1009. doi: 10.1007/s007020170018.
7
[History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Vopr Med Khim. 1997 Nov-Dec;43(6):482-93.
8
(-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
J Am Geriatr Soc. 1992 Aug;40(8):839-47. doi: 10.1111/j.1532-5415.1992.tb01860.x.
9
Manganese neurotoxic time course is not influenced by L-deprenyl systemic treatment: influence of L-deprenyl in manganese neurotoxic time course.
Brain Res. 2010 Mar 4;1317:277-85. doi: 10.1016/j.brainres.2009.12.066. Epub 2010 Jan 4.
10
A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Life Sci. 2003 Apr 25;72(23):2641-8. doi: 10.1016/s0024-3205(03)00174-7.
引用本文的文献
1
Revisiting the Role of Astrocytic MAOB in Parkinson's Disease.
Int J Mol Sci. 2022 Apr 18;23(8):4453. doi: 10.3390/ijms23084453.
2
Binge ethanol exposure increases the Krüppel-like factor 11-monoamine oxidase (MAO) pathway in rats: Examining the use of MAO inhibitors to prevent ethanol-induced brain injury.
Neuropharmacology. 2016 Jun;105:329-340. doi: 10.1016/j.neuropharm.2016.01.024. Epub 2016 Jan 22.
3
Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.
Transl Neurodegener. 2013 Sep 8;2(1):19. doi: 10.1186/2047-9158-2-19.
4
Perspectives on MAO-B in aging and neurological disease: where do we go from here?
Mol Neurobiol. 2004 Aug;30(1):77-89. doi: 10.1385/MN:30:1:077.
5
Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl.
Br J Pharmacol. 1999 Dec;128(8):1754-60. doi: 10.1038/sj.bjp.0702940.
6
Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
J Psychiatry Neurosci. 1999 May;24(3):234-43.
本文引用的文献
1
Protein measurement with the Folin phenol reagent.
J Biol Chem. 1951 Nov;193(1):265-75.
2
Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rat.
Free Radic Biol Med. 1996;20(1):53-61. doi: 10.1016/0891-5849(95)02025-x.
3
Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum.
Neurosci Lett. 1993 Apr 2;152(1-2):113-6. doi: 10.1016/0304-3940(93)90496-8.
4
Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence.
Life Sci. 1993;52(3):281-8. doi: 10.1016/0024-3205(93)90219-s.
5
Reduction in glial fibrillary acidic protein mRNA abundance induced by (-)-deprenyl and other monoamine oxidase B inhibitors in C6 glioma cells.
J Neurochem. 1993 Oct;61(4):1573-6. doi: 10.1111/j.1471-4159.1993.tb13660.x.
6
Low selenium diet affects monoamine turnover differentially in substantia nigra and striatum.
J Neurochem. 1993 Oct;61(4):1302-7. doi: 10.1111/j.1471-4159.1993.tb13622.x.
7
L-deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain.
Neuroreport. 1993 Jul;4(7):955-8. doi: 10.1097/00001756-199307000-00030.
8
Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease.
J Neural Transm Park Dis Dement Sect. 1993;5(3):193-202. doi: 10.1007/BF02257674.
9
The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
J Neural Transm Suppl. 1993;40:69-91.
10
Chronic treatment of aged mice with L-deprenyl produces marked striatal MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation.
Neurobiol Aging. 1993 Sep-Oct;14(5):431-40. doi: 10.1016/0197-4580(93)90101-g.
Zotero 插件